Accounting for Nonadherence

Erica S Spatz^{1

2}, Jeptha P Curtis^{3

2}

Affiliations

¹ Department of Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT (J.P.C., E.S.S.).
² Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT (J.P.C., E.S.S.).
³ Department of Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT (J.P.C., E.S.S.) jeptha.curtis@yale.edu.

Editorial

Erica S Spatz et al. Circulation. 2018.

. 2018 May 15;137(20):2139-2141.

doi: 10.1161/CIRCULATIONAHA.118.033532.

Erica S Spatz^{1

2}, Jeptha P Curtis^{3

2}

¹ Department of Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT (J.P.C., E.S.S.).
² Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT (J.P.C., E.S.S.).
³ Department of Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT (J.P.C., E.S.S.) jeptha.curtis@yale.edu.

No abstract available

Keywords: Editorials; drugs; myocardial infarction; pharmacology; prevention; statins.

Comment on

Hospital Variation in Adherence Rates to Secondary Prevention Medications and the Implications on Quality.
Mathews R, Wang W, Kaltenbach LA, Thomas L, Shah RU, Ali M, Peterson ED, Wang TY. Mathews R, et al. Circulation. 2018 May 15;137(20):2128-2138. doi: 10.1161/CIRCULATIONAHA.117.029160. Epub 2018 Jan 31. Circulation. 2018. PMID: 29386204 Free PMC article.